| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514253050 | Isoquinolines (including hydrogenated) | 35 |
| 20080227792 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters - Novel compounds of formula (I), pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase is beneficial. | 09-18-2008 |
| 20080255145 | Thiadiazole compounds and methods of use - The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders. | 10-16-2008 |
| 20080269243 | Thiadiazole compounds and methods of use - The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders. | 10-30-2008 |
| 20080275056 | Pyrazole-Isoquinoline Urea Derivatives as P38 Kinase Inhibitors - The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof. | 11-06-2008 |
| 20090023746 | COMPOUNDS AND THEIR USES 707 - The present invention relates to isoquinolinone derivatives of formula (I): | 01-22-2009 |
| 20090036465 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION - Methods for treatment of pulmonary hypertension include administration of a first amount of treprostinil and administration of a second amount of a Rho kinase inhibitor such that the first amount and the second amount form together an amount effective for pulmonary hypertension treatment. Kits for treatment pulmonary hypertension are also disclosed. | 02-05-2009 |
| 20090054453 | Novel Tetralins as 5-HT6 Modulators - The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, wherein Q, R | 02-26-2009 |
| 20090118299 | AGENT FOR PREVENTION OR TREATMENT OF GLAUCOMA - There is Provided an Agent for Prevention of glaucoma or an agent for prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. An agent for prevention or treatment of glaucoma comprising a Rho kinase inhibitor and a carbonic anhydrase inhibitor in combination. | 05-07-2009 |
| 20090131451 | Diagnosis and treatment of type 2 diabetes and other disorders - The present application features the use of the somatostatin subtype 3 receptor (SST3) as a target for affecting insulin secretion and for diagnosing diabetes related disorders. Glucose stimulated insulin secretion was found to be stimulated by knocking down expression of SST3 and through the use of a SST3 selective antagonist. | 05-21-2009 |
| 20090143402 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS - Isoquinolone derivatives of the general formula | 06-04-2009 |
| 20090176798 | New compounds III - The present application relates to new compounds of formula (I), | 07-09-2009 |
| 20100041671 | Methods for treating glaucoma - A method for treating glaucoma comprising administering to a patient pharmaceutically effective amounts of a Rho kinase inhibitor and a prostaglandin. | 02-18-2010 |
| 20100063060 | Therapeutic agent for glaucoma comprising Rho Kinhase inhibitor and prostaglandin - A combination of a Rho kinase inhibitor and a prostaglandin as a therapeutic agent for treating glaucoma. The actions of reducing intraocular pressure are complemented and/or enhanced by combining a Rho kinase inhibitor with a prostaglandin. Each of the Rho kinase inhibitor and the prostaglandin can be administered in combination or in a mixture. | 03-11-2010 |
| 20100137331 | Quinolines Useful as Modulators of ION Channels - The present invention relates to compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 06-03-2010 |
| 20110130407 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS - Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia. | 06-02-2011 |
| 20110152286 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS - The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. | 06-23-2011 |
| 20110237600 | COMPOUNDS FOR IMPROVING LEARNING AND MEMORY - The present invention provides a compound of Formula I: (I) and methods for improving memory in a subject by administering a therapeutically effective amount of the compound. | 09-29-2011 |
| 20110263610 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb). | 10-27-2011 |
| 20120040994 | THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDIN - A therapeutic composition for treating glaucoma or for reducing intraocular pressure containing a combination of pharmaceutically effective amounts of drugs including (i) a Rho kinase inhibitor selected from the group consisting of (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and 1-(5-isoquinolinesulfonyl)-homopiperazine, or a salt thereof and (ii) a prostaglandin which is latanoprost or a salt of latanoprost, and (iii) optionally a pharmaceutically acceptable carrier. A therapeutic composition for treating glaucoma or for reducing intraocular pressure containing a combination of pharmaceutically effective amounts of drugs comprising (i) a Rho kinase which is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide or a slat thereof and (ii) a prostaglandin which is isopropyl unoprostone or a salt thereof, and (iii) optionally a pharmaceutically acceptable carrier. | 02-16-2012 |
| 20120129871 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction - A crystalline form of (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, | 05-24-2012 |
| 20130072499 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS - The present invention relates to novel piperazine compounds; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca | 03-21-2013 |
| 20130158044 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS - The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. | 06-20-2013 |
| 20130245036 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION - A crystalline form of (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively. | 09-19-2013 |
| 20130274269 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE - The present invention provides a novel isoquinoline-6-sulfonamide derivative that is useful as a medicine. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt, wherein R | 10-17-2013 |
| 20140038986 | MARKERS ASSOCIATED WITH HUMAN DOUBLE MINUTE 2 INHIBITORS - The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Human Double Minute inhibitors (MDM2i), methods of determining the sensitivity of a cell to an MDM2i by measuring biomarkers and methods of screening for candidate MDM2i. | 02-06-2014 |
| 20140163039 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS - The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. | 06-12-2014 |
| 20140288088 | Inhibitors of the Renal Outer Medullary Potassium Channel - The present invention provides compounds of Formula I | 09-25-2014 |
| 20150011562 | BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE - Novel benzamide derivatives of formula (I) | 01-08-2015 |
| 20150329483 | Methods and Pharmaceutical Compositions for the Treatment of X-Linked Charcot-Marie-Tooth - The present invention relates to methods and pharmaceutical compositions for the treatment of X-linked Charcot-Marie-Tooth. In particular, the present invention relates to a method for the treatment of CMTX in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of CamKII activity or expression. | 11-19-2015 |
| 20150353498 | SUBSTITUTED ISOQUINOLINES AS CRTH2 RECEPTOR MODULATORS - The invention provides certain substituted isoquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters. The invention also provides pharmaceutical compositions comprising for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function. | 12-10-2015 |
| 20160030410 | AGENT FOR PROMOTING CORNEAL ENDOTHELIAL CELL ADHESION - The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium. | 02-04-2016 |
| 20160051548 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders - The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. | 02-25-2016 |
| 20160136159 | Method for Treating Peripheral Neuropathy - A method of treating or preventing peripheral neuropathy in a subject determined to be in need thereof comprising: topically administering to the subject an anti-peripheral neuropathic compound acting as GFRα3 type receptor agonist. | 05-19-2016 |
| 20160137632 | BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE - Novel benzamide derivatives of formula (I) | 05-19-2016 |
| 20220133714 | EXTRACELLULAR MATRIX MODULATING AGENT - The present invention provide an agent for modulating expression of extracellular matrix by corneal endothelial cells. The present invention pertains to an agent for modulating expression of extracellular matrix by corneal endothelial cells containing, 1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof. | 05-05-2022 |
